tallózása szerző szerint "Palumbo A"

A találatok rendezése: Rendezés: Találatok:

  • Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. 
    Stewart AK; Rajkumar SV; Dimopoulos MA; Masszi, Tamás; Spicka I; Oriol A; Hajek R; Rosinol L; Siegel DS; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak AJ; San-Miguel JF; Ludwig H; Wang M; Maisnar V; Minarik J; Bensinger WI; Mateos MV; Ben-Yehuda D; Kukreti V; Zojwalla N; Tonda ME; Yang X; Xing B; Moreau P; Palumbo A; the ASPIRE Investigators (2014)
    Background Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase ...
  • Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment 
    Dimopoulos MA; Stewart AK; Masszi, Tamás; Spicka I; Oriol A; Hajek R; Rosinol L; Siegel D; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak A; San-Miguel J; Ludwig H; Ro S; Aggarwal S; Moreau P; Palumbo A (2017)
    Carfilzomib, a proteasome inhibitor, is approved as monotherapy and in combination with dexamethasone or lenalidomide-dexamethasone (Rd) for relapsed or refractory multiple myeloma. The approval of carfilzomib-lenalidomi ...
  • Elevated troponin i levels but not low grade chronic inflammation is associated with cardiac-specific mortality in stable hemodialysis patients 
    Alam A; Palumbo A; Mucsi, István; Barré PE; Sniderman AD (2013)
    Background: Elevated cardiac troponin I (TnI) levels are associated with all-cause mortality in stable hemodialysis patients. Their relationship to cardiac-specific death has been inconsistent, and the reason for their ...